Linked Life Data

19067673

Source:http://linkedlifedata.com/resource/pubmed/id/19067673

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-25
pubmed:abstractText
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors have been used clinically for lowering total and low-density lipoprotein cholesterol. Interindividual pharmacological differences observed with this treatment have been attributed to genetic differences. The aim of this study was to assess the association in the low-density lipoprotein cholesterol reduction by atorvastatin and (TTA)n polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene in patients with coronary artery disease. Changes in total cholesterol levels, triglycerides, high-sensitivity C-reactive protein and free F(2)-isoprostanes were also evaluated. In an open study, patients received 40 mg atorvastatin daily for 8 weeks. Genotyping was done through polymerase chain reaction. The genotype distribution of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (TTA)n polymorphism was: >10/>10 in 22 out of 64 patients (34%), >10/10 in 14 out of 64 patients (22%) and 10/10 in 28 out of 64 patients (44%). The reduction of low-density lipoprotein cholesterol levels by atorvastatin was not different between allelic variants (TTA)n repeat polymorphism. Reductions in high-sensitivity C-reactive protein were observed in atorvastatin-treated patients with alleles >10/>10 and 10/10. Free F(2)-isoprostanes and total cholesterol were also significantly lower after treatment for all alleles, irrespective of type of polymorphism. In conclusion, the changes induced by atorvastatin treatment on low-density lipoprotein cholesterol, total cholesterol, triglycerides, high-sensitivity C-reactive protein and free F(2)-isoprostane concentrations were not related to the presence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase polymorphism (TTA)n.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1742-7843
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
104
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
211-5
pubmed:meshHeading
pubmed-meshheading:19067673-Aged, pubmed-meshheading:19067673-Alleles, pubmed-meshheading:19067673-C-Reactive Protein, pubmed-meshheading:19067673-Cholesterol, pubmed-meshheading:19067673-Cholesterol, LDL, pubmed-meshheading:19067673-Coronary Artery Disease, pubmed-meshheading:19067673-Female, pubmed-meshheading:19067673-Follow-Up Studies, pubmed-meshheading:19067673-Heptanoic Acids, pubmed-meshheading:19067673-Humans, pubmed-meshheading:19067673-Hydroxymethylglutaryl CoA Reductases, pubmed-meshheading:19067673-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:19067673-Male, pubmed-meshheading:19067673-Middle Aged, pubmed-meshheading:19067673-Polymerase Chain Reaction, pubmed-meshheading:19067673-Polymorphism, Genetic, pubmed-meshheading:19067673-Pyrroles, pubmed-meshheading:19067673-Triglycerides, pubmed-meshheading:19067673-Trinucleotide Repeats
pubmed:year
2009
pubmed:articleTitle
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
pubmed:affiliation
FONDAP Center for Molecular Cell Studies, Clinical Hospital, University of Chile, Santiago, Chile.
pubmed:publicationType
Journal Article, Controlled Clinical Trial, Research Support, Non-U.S. Gov't